Eczema Clinical Research Studies

Interested in joining a clinical research trial?

Atopic dermatitis, or eczema, is the most common chronic inflammatory, pruritic skin disease. It causes intense itching and scratching which leads to a severe rash. Recent eczema studies have given researchers more information about this disease, which is leading to a better understanding of the ailment and new treatment options. There are currently a variety of eczema studies available at our center for patients with mild to severe atopic dermatitis. These studies include treatments such as biologics (complicated molecules that are manufactured within a living organism), a topical gel, and an oral medication designed to help decrease extremely itchy skin involved with eczema. These study medications are at the forefront of current medicine and are provided at absolutely no cost, and with no insurance needed. You may also be reimbursed for your time and travel and will receive care from a physician affiliated with the Clinical Research Center of Alabama.

For more information on any of the following eczema clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing wodonnell@alabamaallergy.com

Biologic Injection Study

Age 12-17

Leo1334

This study is to evaluate the efficacy and safety of Tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy. There are a total of 29 visits over a span of 72 weeks.

Biologic Injection Study

Ages 6 months-6 years

Rengeneron 1539

A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to < 6years with severe atopic dermatitis.

Oral Medication in comparison and in combination with Dupilumab

Age 19+

Pfizer1029

The purpose of this study is to compare the safety and efficacy of the study medication (PF-04965842) compared to dupilumab and placebo in adult subjects on background topical therapy with moderate to severe atopic dermatitis.

Biologic Injection Study

Age 19+

Glenmark

This research study is being done to evaluate if the investigational drug, GBR 830, is safe and effective in subjects with moderate to severe atopic dermatitis. This study is also looking at the biological activity of GBR 830 and how it is eliminated from the body.

Oral Medication

Age 19-70

Vanda

The purpose of this study is to evaluate the effect of an investigational drug called Tradipitant on symptoms associated with atopic dermatitis with atopic dermatitis and to assess the safety of Tradipitant.

Oral Medication - Add-On Therapy

Age 12-75

AbbVie

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) and adults (18-75 years of age with moderate to severe atopic dermatitis (AD).

Topical Cream

Age 19+

Leo1275

The purpose of this study is to evaluate the safety and effectiveness of Delgocitinib cream on adult patients with moderate to severe atopic dermatitis.

Biological Injection Study

Age 19+

Genentech AD

The purpose if this study is to compare the safety and effects, good or bad, of MSTT1041A versus placebo on patients with moderate to severe atopic dermatitis. In this study, you will get either MSTT1041A or placebo.

Oral Medication Add-on therapy

Age 12-17

Pfizer1036

The purpose of this study is to compare the efficacy and safety of two doses of the study drug (PF-04965842) with a placebo when taken together with medicated therapy applied to the skin.

Biological Injection Study

Age 19-75

Regeneron1805

The main purpose of this study is to determine how well different doses of REGN3500 work in treating moderate-to-severe eczema and if REGN3500 is safe.

Become a Participant in our Eczema Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.